Suchergebnisse

Adenovirus Types 4 and 7 (Ad4 and Ad7) are associated with acute respiratory distress (ARD). In order to prevent widespread Ad-associated ARD (Ad-ARD) the United States military immunizes new recruits using a safe and effective lyophilized wildtype Ad4 and Ad7 delivered orally in an enteric-coated capsule. We cloned Ad4 and Ad7 and modified them to express either a GFP-Luciferase (GFPLuc) fusion gene or a centralized influenza H1 hemagglutinin (HA1-con). BALB/c mice were injected with GFPLuc expressing viruses intramuscularly (i.m.) and intranasally (i.n.). Ad4 induced significantly higher luciferase expression levels as compared with Ad7 by both routes. Ad7 transduction was restored using a human CD46+ transgenic mouse model. Mice immunized with serial dilutions of viruses expressing the HA1-con influenza vaccine gene were challenged with 100 MLD50 of influenza virus. Ad4 protected BALB/c mice at a lower dose by i.m. immunization as compared with Ad7. Unexpectedly, there was no difference in protection by i.n. immunization. Although Ad7 i.m. transduction was restored in CD46+ transgenic mice, protection against influenza challenge required even higher doses as compared with the BALB/c mice. However, Ad7 i.n. immunized CD46+ transgenic mice were better protected as compared with Ad4. Interestingly, the restoration of Ad7 transduction in CD46+ mice did not increase vaccine efficacy and indicates that Ad7 may transduce a different subset of cells through alternative receptors in the absence of CD46. These data indicate that both Ad4 and Ad7 can effectively induce anti-H1N1 immunity against a heterologous challenge using a centralized H1 gene. Future studies in non-human primates or human clinical trials will determine the overall effectiveness of Ad4 and Ad7 as vaccines for influenza.

Abstract
Conservative religious ideologies have been linked to vaccine hesitancy. Yet, little is known about how paranormal beliefs relate to vaccine confidence and uptake. We hypothesize that paranormal beliefs will be negatively related to both confidence and uptake due to their association with lower levels of trust in science and a greater acceptance of conspiratorial beliefs. We test this hypothesis using a new nationally representative sample of U.S. adults fielded in May and June of 2021 by NORC. Using regression models with a sample of 1,734, we find that paranormal beliefs are negatively associated with general vaccine confidence, COVID-19 vaccine confidence, and COVID-19 vaccine uptake. These associations are partially or fully attenuated net of trust in science and conspiratorial belief. Although not a focus of the study, we also find that Christian nationalism's negative association with the outcomes is fully accounted for by measures of trust in science and conspiratorial beliefs.

International audience ; In the recent years, Ebola virus has been responsible for several major epidemics. Research efforts have allowed the development and evaluation in the field of several vaccine candidates. At present, two of them are already approved and used in the fight against the virus in the Democratic Republic of Congo. This review aims to describe the different candidates, the clinical trials that have been conducted as well as the first results in the field. ; Ces dernières années, le virus Ebola a été responsable d'épidémies de grande ampleur. Les efforts de recherche ont permis la mise au point et l'évaluation sur le terrain de plusieurs candidats vaccins. À l'heure actuelle, deux sont déjà homologués et utilisés dans la lutte contre le virus en République démocratique du Congo. Cette revue se propose de faire le point sur les différents candidats vaccins, les essais cliniques qui ont été menés et les premiers résultats de terrain.

International audience ; In the recent years, Ebola virus has been responsible for several major epidemics. Research efforts have allowed the development and evaluation in the field of several vaccine candidates. At present, two of them are already approved and used in the fight against the virus in the Democratic Republic of Congo. This review aims to describe the different candidates, the clinical trials that have been conducted as well as the first results in the field. ; Ces dernières années, le virus Ebola a été responsable d'épidémies de grande ampleur. Les efforts de recherche ont permis la mise au point et l'évaluation sur le terrain de plusieurs candidats vaccins. À l'heure actuelle, deux sont déjà homologués et utilisés dans la lutte contre le virus en République démocratique du Congo. Cette revue se propose de faire le point sur les différents candidats vaccins, les essais cliniques qui ont été menés et les premiers résultats de terrain.

International audience ; In the recent years, Ebola virus has been responsible for several major epidemics. Research efforts have allowed the development and evaluation in the field of several vaccine candidates. At present, two of them are already approved and used in the fight against the virus in the Democratic Republic of Congo. This review aims to describe the different candidates, the clinical trials that have been conducted as well as the first results in the field. ; Ces dernières années, le virus Ebola a été responsable d'épidémies de grande ampleur. Les efforts de recherche ont permis la mise au point et l'évaluation sur le terrain de plusieurs candidats vaccins. À l'heure actuelle, deux sont déjà homologués et utilisés dans la lutte contre le virus en République démocratique du Congo. Cette revue se propose de faire le point sur les différents candidats vaccins, les essais cliniques qui ont été menés et les premiers résultats de terrain.

International audience ; In the recent years, Ebola virus has been responsible for several major epidemics. Research efforts have allowed the development and evaluation in the field of several vaccine candidates. At present, two of them are already approved and used in the fight against the virus in the Democratic Republic of Congo. This review aims to describe the different candidates, the clinical trials that have been conducted as well as the first results in the field. ; Ces dernières années, le virus Ebola a été responsable d'épidémies de grande ampleur. Les efforts de recherche ont permis la mise au point et l'évaluation sur le terrain de plusieurs candidats vaccins. À l'heure actuelle, deux sont déjà homologués et utilisés dans la lutte contre le virus en République démocratique du Congo. Cette revue se propose de faire le point sur les différents candidats vaccins, les essais cliniques qui ont été menés et les premiers résultats de terrain.

The concept of immunization was started in Japan in 1849 when Jenner's cowpox vaccine seed was introduced, and the current immunization law was stipulated in 1948. There have been two turning points for amendments to the immunization law: the compensation remedy for vaccine-associated adverse events in 1976, and the concept of private vaccination in 1994. In 1992, the regional Court of Tokyo, not the Supreme Court, decided the governmental responsibility on vaccine-associated adverse events, which caused the stagnation of vaccine development. In 2010, many universal vaccines became available as the recommended vaccines, but several vaccines, including mumps, zoster, hepatitis B, and rota vaccines, are still voluntary vaccines, not universal routine applications. In this report, immunization strategies and vaccine development are reviewed for each vaccine item and future vaccine concerns are discussed.

BACKGROUND: Public confidence in vaccination is vital to the success of immunisation programmes worldwide. Understanding the dynamics of vaccine confidence is therefore of great importance for global public health. Few published studies permit global comparisons of vaccination sentiments and behaviours against a common metric. This article presents the findings of a multi-country survey of confidence in vaccines and immunisation programmes in Georgia, India, Nigeria, Pakistan, and the United Kingdom (UK) - these being the first results of a larger project to map vaccine confidence globally. METHODS: Data were collected from a sample of the general population and from those with children under 5 years old against a core set of confidence questions. All surveys were conducted in the relevant local-language in Georgia, India, Nigeria, Pakistan, and the UK. We examine confidence in immunisation programmes as compared to confidence in other government health services, the relationships between confidence in the system and levels of vaccine hesitancy, reasons for vaccine hesitancy, ultimate vaccination decisions, and their variation based on country contexts and demographic factors. RESULTS: The numbers of respondents by country were: Georgia (n=1000); India (n=1259); Pakistan (n=2609); UK (n=2055); Nigerian households (n=12554); and Nigerian health providers (n=1272). The UK respondents with children under five years of age were more likely to hesitate to vaccinate, compared to other countries. Confidence in immunisation programmes was more closely associated with confidence in the broader health system in the UK (Spearman's ρ=0.5990), compared to Nigeria (ρ=0.5477), Pakistan (ρ=0.4491), and India (ρ=0.4240), all of which ranked confidence in immunisation programmes higher than confidence in the broader health system. Georgia had the highest rate of vaccine refusals (6 %) among those who reported initial hesitation. In all other countries surveyed most respondents who reported hesitating to vaccinate went on to ...

Background. Public confidence in vaccination is vital to the success of immunisation programmes worldwide. Understanding the dynamics of vaccine confidence is therefore of great importance for global public health. Few published studies permit global comparisons of vaccination sentiments and behaviours against a common metric. This article presents the findings of a multi-country survey of confidence in vaccines and immunisation programmes in Georgia, India, Nigeria, Pakistan, and the United Kingdom (UK) – these being the first results of a larger project to map vaccine confidence globally. Methods. Data were collected from a sample of the general population and from those with children under 5 years old against a core set of confidence questions. All surveys were conducted in the relevant local-language in Georgia, India, Nigeria, Pakistan, and the UK. We examine confidence in immunisation programmes as compared to confidence in other government health services, the relationships between confidence in the system and levels of vaccine hesitancy, reasons for vaccine hesitancy, ultimate vaccination decisions, and their variation based on country contexts and demographic factors. Results. The numbers of respondents by country were: Georgia (n=1000); India (n=1259); Pakistan (n=2609); UK (n=2055); Nigerian households (n=12554); and Nigerian health providers (n=1272). The UK respondents with children under five years of age were more likely to hesitate to vaccinate, compared to other countries. Confidence in immunisation programmes was more closely associated with confidence in the broader health system in the UK (Spearman's ρ=0.5990), compared to Nigeria (ρ=0.5477), Pakistan (ρ=0.4491), and India (ρ=0.4240), all of which ranked confidence in immunisation programmes higher than confidence in the broader health system. Georgia had the highest rate of vaccine refusals (6 %) among those who reported initial hesitation. In all other countries surveyed most respondents who reported hesitating to vaccinate went on to ...

"Though small, the recent protests we've seen across the U.S. signal what is likely to come as governments grapple with how to move forward, particularly if a vaccine against SARS-CoV-2, the virus causing the pandemic becomes available."

The fateful year of 2020 will go down the annals of history as the year during which global pandemic COVID-19 spread across the globe causing widespread confusion, panic, chaos and mayhem. As this respiratory disease - which primarily affects lungs and, in case of complications, many other organs of body - spread rapidly across the world, scientists and biologists began their hectic efforts to develop protocols for treatment and prevention of this disease. As is the case with all other viral diseases, the best tool that can save humanity from this ongoing pandemic is a potent vaccine. Realizing the urgency of the matter at hand and the enormous potential of revenue generation, a number of companies started this race of developing vaccine at an accelerated rate. From securing funding from research to gaining approval of regulatory authorities after clinical trials, it normally takes a long time to develop a vaccine. However, owing to the great global demand and willingness of governments to pro-vide generous funding, vaccines for COVID-19 have been developed at a much faster pace than ever before.

The fateful year of 2020 will go down the annals of history as the year during which global pandemic COVID-19 spread across the globe causing widespread confusion, panic, chaos and mayhem. As this respiratory disease-which primarily affects lungs and, in case of complications, many other organs of body-spread rapidly across the world, scientists and biologists began their hectic efforts to develop proto-cols for treatment and prevention of this disease. As is the case with all other viral diseases, the best tool that can save humanity from this ongoing pandemic is a potent vaccine. Realizing the urgency of the matter at hand and the enormous potential of revenue generation, a number of companies started this race of developing vaccine at an accelerated rate. From securing funding from research to gaining approval of regulatory authorities after clinical trials, it norm-ally takes a long time to develop a vaccine. However, owing to the great global demand and willingness of governments to provide generous funding, vaccines for COVID-19 have been developed at a much faster pace than ever before.

Vaccine Supply and Innovation -- Copyright -- Preface -- Contents -- Vaccine Supply and Innovation -- 1 Summary -- OVERVIEW -- VACCINE AVAILABILITY: MAJOR BARRIERS AND IMPEDIMENTS -- Impediments to Vaccine Innovation -- ECONOMIC CHARACTERISTICS OF THE VACCINE INDUSTRY -- VACCINE INJURY -- THE LEGAL SITUATION AND ITS CONSEQUENCES -- CONSEQUENCES OF THE STATE OF VACCINE INJURY LIABILITY LAW FOR VACCINE PRODUCTION AND INNOVATION -- A NATIONAL VACCINE COMMISSION -- COMPENSATION AND LIABILITY FOR VACCINE-RELATED INJURY -- 2 Vaccines: Past, Present, and Future -- TYPES OF IMMUNIZATION -- HISTORY OF IMMUNIZATION -- THE PRESENT -- Development of Vaccines and Recommendations for Vaccine Use -- THE FUTURE -- REFERENCES AND NOTES -- 3 Vaccine Availability: Concerns, Barriers, and Impediments -- CONCERNS ABOUT THE CURRENT SITUATION -- Supply -- Stockpiling of Vaccines -- Problems with Sole Reliance on Foreign Manufacturers -- Federal Action to Ensure Vaccine Supply -- BARRIERS AND IMPEDIMENTS TO VACCINE INNOVATION -- Identification of Need and Establishing Priorities -- Establishing the Technical Feasibility of Vaccine Development -- Economic Disincentives to Innovation and Production -- Factors Influencing the Market for Vaccines -- VACCINE UTILIZATION -- System Factors -- Client Factors -- Provider Factors -- CONCLUSIONS -- Barriers and Impediments to Vaccine Innovation -- REFERENCES AND NOTES -- 4 Economic Aspects of Vaccine Innovation and Manufacturing -- POTENTIAL CAUSES OF INDUSTRY DECLINE -- Property Rights and Innovation -- Regulation -- Market Size -- Liability and Risk -- DESCRIPTIVE STATISTICS -- The Market and Participants -- Pricing -- Research and Development -- CONCLUSIONS -- REFERENCES AND NOTES -- 5 Vaccine Injury -- The Pertussis Controversy -- Identifying Individuals at High Risk of Adverse Effects -- VACCINES USED IN CHILDHOOD.